FDA Servicing vs Remanufacturing Decision Tree for Medical Devices: How to Classify Your Activities Under the May 2024 Final Guidance

Why the Servicing vs Remanufacturing Distinction Matters Now

On May 10, 2024, the FDA issued its final guidance document on Remanufacturing of Medical Devices, closing a regulatory ambiguity that had persisted for years. The guidance establishes a clear framework for determining whether activities performed on a finished medical device after distribution constitute "servicing" or "remanufacturing" — and the regulatory consequences of that classification are significant.

Servicing — defined as repair and/or preventive or routine maintenance of one or more parts in a finished device, after distribution, for purposes of returning it to the safety and performance specifications established by the OEM and to meet its original intended use — is largely unregulated by the FDA when performed by independent third parties. The FDA does not require third-party servicers to register with the agency, maintain a quality system compliant with 21 CFR Part 820, or submit premarket notifications for their servicing activities.

Remanufacturing — defined as processing, conditioning, renovating, repackaging, restoring, or any other act done to a finished device that significantly changes the finished device's performance or safety specifications, or intended use — triggers the full scope of FDA regulatory requirements. Remanufacturers must register and list with the FDA, comply with the Quality Management System Regulation (QMSR, effective February 2, 2026), submit premarket applications (510(k), PMA, or De Novo as applicable), report adverse events under 21 CFR Part 803, and comply with all other applicable requirements under the Federal Food, Drug, and Cosmetic Act.

The critical insight from the final guidance is this: the FDA determines whether an activity is servicing or remanufacturing based on the specific tasks performed on the device, not based on the entity's self-identified designation. A company that calls itself a "service provider" but performs activities that significantly change the device's safety or performance specifications is a remanufacturer in the FDA's view — with all the regulatory obligations that entails.

This matters for three audiences:

• OEMs, who need to understand what activities their own service organizations and authorized service partners perform, and what activities third parties may be performing on their devices
• Third-party servicers and independent service organizations (ISOs), who need to honestly assess whether their activities cross the line into remanufacturing — because the FDA can take enforcement action against entities that perform remanufacturing without complying with regulatory requirements
• Hospital biomedical engineering and HTM teams, who perform in-house maintenance and repair and need to understand when their activities may constitute remanufacturing

The FDA's Definitions: Exact Regulatory Language

Servicing (FDA Guidance Definition)

The FDA's May 2024 guidance on Remanufacturing of Medical Devices defines "servicing" as:

Repair and/or preventive or routine maintenance of one or more parts in a finished device, after distribution, for purposes of returning it to the safety and performance specifications established by the OEM and to meet its original intended use.

The definition explicitly excludes "activities that significantly change the finished device's safety or performance specifications, or intended use."

Key elements of this definition:

• The activity must occur after distribution of the device
• The purpose must be returning the device to OEM-established specifications
• The device must continue to meet its original intended use
• Any activity that significantly changes safety or performance specifications or intended use is excluded

Remanufacturing (21 CFR 820.3(w))

The FDA defines "remanufacture" as:

Process, condition, renovate, repackage, restore, or any other act done to a finished device that significantly changes the finished device's performance or safety specifications, or intended use.

Key elements:

• The activity is performed on a finished device (already distributed)
• The activity "significantly changes" the device's performance specifications, safety specifications, or intended use
• The "significantly changes" threshold is the critical discriminator

The Morgan Lewis analysis of the final guidance notes that although several commenters on the draft version raised concerns about the FDA's continued hands-off approach for third-party servicing, the final guidance includes no reversal of this policy — meaning independent third parties performing only servicing activities continue to benefit from limited FDA oversight, but those whose activities constitute remanufacturing face full regulatory exposure.

The 6 Guiding Principles for Classification

The FDA's final guidance provides six guiding principles that entities should apply when determining whether their activities constitute servicing or remanufacturing:

Principle 1: Assess Whether There Is a Change to the Intended Use

If the activity changes the device's intended use — meaning the indications for use, the patient population, the clinical setting, or the mode of operation — it is almost certainly remanufacturing. Intended use is established through the device's labeling, including the indications for use statement in the premarket submission.

This is the most straightforward principle. If you are modifying a device to be used for a different purpose than what the OEM designed and labeled it for, you are remanufacturing.

Principle 2: Determine Whether Activities Significantly Change Safety or Performance Specifications

This is where the analysis becomes nuanced. The FDA defines "specifications" broadly to include dimensional specifications, material specifications, performance parameters, and functional characteristics. The question is whether the activity "significantly changes" any of these.

The guidance acknowledges that "significant change" is context-dependent and must be assessed on a case-by-case basis. Factors to consider include:

• Whether the change alters the device's risk profile
• Whether the change affects the device's ability to meet its cleared or approved performance parameters
• Whether the change introduces new failure modes or increases the severity of existing failure modes
• Whether the change requires different operator training or user instructions

Principle 3: Evaluate Whether Any Changes Require a New Marketing Submission

If the change to the device would require a new 510(k), PMA supplement, or other premarket submission, this strongly suggests the activity is remanufacturing. The guidance uses this as a cross-check — if a change is significant enough to require regulatory notification or approval, it is likely significant enough to constitute remanufacturing.

Principle 4: Assess Component, Part, or Material Dimensional and Performance Specifications

When replacing or modifying components, compare the replacement part's specifications against the OEM's original specifications. Using an identical part from the OEM — same part number, same specifications, same supplier — is almost always servicing. Using a different part, even if it is "equivalent" or "better," requires analysis:

• Does the replacement part have identical dimensional specifications? Even small dimensional differences can affect device performance.
• Does the replacement part have identical material specifications? Different materials may have different biocompatibility profiles, different mechanical properties, or different aging characteristics.
• Does the replacement part meet the same performance specifications? A part that exceeds the OEM's specifications may still constitute a significant change if it alters the device's performance profile.

Principle 5: Employ a Risk-Based Approach

The guidance recommends using a risk-based approach consistent with ISO 14971 to evaluate the impact of the activity on the device's safety and effectiveness. This means:

• Identifying the hazards associated with the modification
• Estimating the risk (severity × probability) for each hazard
• Evaluating whether the risk has been introduced or increased beyond what was established in the original risk analysis
• Determining whether new risk control measures are needed

A modification that introduces new risks or increases existing risks above the level accepted in the original risk analysis is more likely to constitute remanufacturing.

Principle 6: Adequately Document Decision-Making

This principle serves two purposes. First, it creates a record that demonstrates the entity's rationale for classifying the activity as servicing or remanufacturing. Second, it provides evidence that the entity applied a structured, good-faith analysis rather than defaulting to "servicing" without proper evaluation.

Documentation should include:

• Description of the activity performed
• Specifications of the original and replacement components or materials (if applicable)
• Risk assessment of the modification's impact on device safety and performance
• Comparison against OEM specifications and labeling
• Basis for the classification determination
• Any testing or verification performed to support the determination

The Decision Flowchart

The final guidance includes a decision flowchart (on page 11 of the guidance document) that provides a structured approach to the classification determination. While the full flowchart is best reviewed in the original document, its logic can be summarized:

Step 1: Does the activity change the device's intended use?

• Yes → Remanufacturing
• No → Continue to Step 2

Step 2: Does the activity significantly change the device's safety specifications?

• Yes → Remanufacturing
• No → Continue to Step 3

Step 3: Does the activity significantly change the device's performance specifications?

• Yes → Remanufacturing
• No → Continue to Step 4

Step 4: Does the activity involve replacing a component with a non-identical part, modifying the device's software, or making any other material change?

• Yes → Conduct full analysis using all six principles; document the determination
• No → Likely servicing

Step 5: Document your determination.

The guidance also includes a set of illustrative examples that demonstrate how the flowchart applies to specific scenarios. These examples are one of the most valuable parts of the guidance because they show the FDA's thinking in concrete terms.

Activities That Are Automatically Classified

The guidance identifies certain activities that are automatically classified as remanufacturing because of their inherent impact on the device's fundamental characteristics:

Automatic Remanufacturing Triggers

Changes to sterilization method. If a device was validated for steam sterilization and the entity changes it to ethylene oxide sterilization, or vice versa, this is remanufacturing. The sterilization method is part of the device's validated specifications.

Changes to reprocessing instructions. Modifying the instructions for how a reusable device should be cleaned, disinfected, or sterilized between uses constitutes remanufacturing. These instructions are part of the device's labeling and are validated as part of the premarket submission.

Changes to control mechanisms. If a device's control system — whether mechanical, electronic, or software-based — is modified, this is likely remanufacturing. Control mechanisms directly affect the device's performance and safety specifications.

Changes to operating principles. Modifying how the device achieves its therapeutic or diagnostic function — changing the mechanism of action — is remanufacturing.

Changes to energy type. If a device was designed to operate on battery power and the entity modifies it to operate on line power, or changes the type of energy the device delivers to the patient, this is remanufacturing.

Software-Specific Classification Rules

The FDA provides specific guidance for software changes, which are frequently the subject of classification disputes:

Generally servicing (software):

• Installing OEM-provided software updates and patches
• Applying OEM-released cybersecurity updates
• Restoring software to the OEM's validated version after a failure
• Reconfiguring software settings within the OEM-specified range

Generally remanufacturing (software):

• Creating custom batch files or scripts that modify device behavior
• Installing non-OEM software or firmware
• Modifying the software's source code
• Changing the device's communication protocols or data processing algorithms
• Adding software features not included in the original OEM configuration

The HIT Consultant analysis of the guidance emphasizes that software changes are often categorized as remanufacturing due to their potential impact on the device's architecture and data processing. The guidance includes a specific list on page 16 that classifies software activities.

Contextual Examples from the Guidance

The FDA includes several detailed examples that illustrate the classification in practice:

Example: Endoscope Lens Replacement

An endoscope lens is cracked. The lens is affixed with an epoxy that is not described in the device's labeling. A servicer removes the cracked lens and replaces it using a different epoxy purchased from a different supplier.

Analysis: The original epoxy was not part of the labeled specifications, so its use in manufacturing was the OEM's process knowledge. The servicer's use of a different epoxy is a material change that could affect the biocompatibility, chemical resistance, or mechanical stability of the lens attachment. This activity requires evaluation against the six guiding principles — and depending on the risk assessment, it could constitute remanufacturing.

Example: Battery Replacement with Identical OEM Part

A defibrillator battery reaches end of life. The servicer replaces it with an identical battery from the OEM, following the OEM's service instructions.

Analysis: This is servicing. The replacement part is identical to the original, the activity follows the OEM's documented procedure, and the purpose is to return the device to its original performance specifications.

Example: Upgrading Monitor Display

A patient monitor has a CRT display that is no longer available. A servicer replaces it with an LCD panel from a different supplier.

Analysis: This is likely remanufacturing. Even if the LCD provides "equivalent" or "better" display performance, it is a different component with different specifications. The change may affect electromagnetic compatibility, power consumption, thermal profile, and display accuracy. A full analysis using the six principles is required.

Regulatory Requirements for Remanufacturers

The final guidance includes a dedicated section (Section VIII) clarifying the regulatory requirements that apply to entities determined to be performing remanufacturing. These requirements are consistent with those for manufacturers:

Registration and listing. Remanufacturers must register their establishment with the FDA and list the devices they remanufacture.

Quality system compliance. Remanufacturers must comply with the QMSR (21 CFR Part 820, incorporating ISO 13485:2016 by reference as of February 2, 2026).

Premarket requirements. Remanufacturers must obtain appropriate premarket clearance or approval (510(k), PMA, De Novo) for devices they remanufacture if the remanufactured device is significantly different from the originally cleared or approved device.

Medical device reporting. Remanufacturers must report adverse events and malfunctions under 21 CFR Part 803.

Corrections and removals. Remanufacturers must report corrections and removals under 21 CFR Part 806.

Labeling. Remanufactured devices must bear appropriate labeling, including identification of the remanufacturer.

The Morgan Lewis analysis notes that it remains unclear how effective FDA oversight can be for third-party servicers who cross the line into remanufacturing, since these entities are not required to register with the FDA and thus are not subject to routine inspection. The guidance relies on third-party servicers to self-assess — but the FDA has stated it can take enforcement action against entities that perform remanufacturing without complying with these requirements.

Labeling Recommendations for Devices Intended to Be Serviced

The guidance includes recommendations for information that should be included in the labeling of devices that are intended to be serviced over their useful life:

• Instructions for performing preventive maintenance and routine servicing
• Specifications for replacement parts and materials (including acceptable alternatives if applicable)
• Test and calibration procedures needed to verify that the device has been returned to OEM specifications after servicing
• Identification of activities that would constitute remanufacturing if performed on this device
• Warnings about modifications that could affect the device's safety or effectiveness
• Contact information for obtaining service manuals, replacement parts, and technical support

These labeling recommendations serve a dual purpose: they help servicers perform appropriate servicing activities, and they help identify activities that cross the line into remanufacturing.

Practical Implementation: Building Your Own Decision Tree

For organizations that regularly perform maintenance, repair, or modification activities on medical devices, the guidance's framework should be operationalized into an internal decision process:

Step 1: Establish a Classification SOP

Create a standard operating procedure that requires every non-routine service activity to be evaluated against the six guiding principles before it is performed. Routine activities that have already been classified (such as replacing batteries with OEM parts per service instructions) can be pre-classified as servicing in the SOP.

Step 2: Create a Classification Checklist

Develop a checklist based on the six principles and the decision flowchart. The checklist should be completed for every activity that is not pre-classified. It should capture:

• Description of the proposed activity
• Whether the activity changes the device's intended use
• Whether the activity changes any safety or performance specification
• Whether the replacement parts or materials are identical to OEM specifications
• Whether a risk assessment has been performed
• Whether any regulatory submission would be required
• The classification determination and its basis

Step 3: Establish a Review Authority

Define who has the authority to make classification determinations. For straightforward cases, a qualified service engineer may be sufficient. For ambiguous cases, involve quality and regulatory personnel. For high-risk devices or activities with significant regulatory exposure, legal counsel may be appropriate.

Step 4: Maintain a Classification Log

Keep a record of all classification determinations. This log serves as evidence of your organization's good-faith application of the guidance and provides a reference for future determinations on similar activities.

Step 5: Train Your Team

Ensure that all personnel who perform service activities understand the distinction between servicing and remanufacturing, know when to escalate for classification review, and understand the regulatory consequences of performing remanufacturing activities without compliance.

Special Considerations for Specific Device Types

Reusable Surgical Instruments

Reusable surgical instruments are frequently serviced — sharpened, reconditioned, and repaired. Servicing is appropriate when the activity returns the instrument to its original specifications. Remanufacturing occurs when the instrument is modified in ways that change its dimensions beyond specification, alter its material, or change its functional characteristics.

Imaging Equipment

Imaging systems are complex, expensive, and typically serviced by OEM-authorized or third-party organizations. Common servicing activities include replacing tubes, calibrating detectors, and updating software. Activities that cross into remanufacturing include modifying the imaging chain with non-OEM components, changing the system's diagnostic algorithms, or altering the system's radiation output characteristics.

Infusion Pumps

Infusion pump servicing includes replacing pump mechanisms, recalibrating flow rates, and updating firmware. Modifications that change the pump's delivery accuracy specifications, alarm thresholds, or drug library configurations beyond OEM parameters would likely constitute remanufacturing.

Endoscopes

Endoscopes are among the most frequently serviced — and most frequently modified — devices in hospitals. The guidance specifically addresses endoscope activities, including lens replacement, channel repair, and biocompatibility considerations for replacement materials.

QMSR Implications

The FDA's Quality Management System Regulation (QMSR), effective February 2, 2026, incorporates ISO 13485:2016 by reference. For entities classified as remanufacturers, this means:

• The full quality management system requirements of ISO 13485 apply, including design controls (Clause 7.3), production controls (Clause 7.5), and risk management integration
• Remanufacturers are subject to the new risk-based FDA inspection process, which evaluates six QMS areas including production and service provision, outsourcing and purchasing, and measurement, analysis, and improvement
• Management review records, internal audit records, and supplier audit records — previously not routinely examined during FDA inspections — are now explicitly reviewable

For servicers whose activities remain within the servicing definition, the QMSR does not directly apply. However, the guidance recommends that servicers maintain documentation of their classification determinations and follow risk-based decision-making processes, which aligns with the principles underlying the QMSR.

Key Takeaways

The FDA's May 2024 final guidance on remanufacturing provides the most detailed framework to date for distinguishing between servicing and remanufacturing of medical devices. The classification is based on the specific activities performed, not on the entity's self-designation. The six guiding principles — intended use, significant change to specifications, marketing submission requirements, component specifications, risk-based approach, and documentation — provide a structured methodology for making this determination.

Organizations that perform service activities on medical devices should operationalize this framework into their standard operating procedures, create classification checklists, establish review authorities, and maintain documentation of all determinations. The regulatory exposure for performing remanufacturing without compliance is real — and the FDA has stated it can take enforcement action against entities that do so.